Skip to main content

Medication Removed from Our Medical Injectables Program

In a previous announcement, we advised that effective March 1, 2018, additional injectable medications would be included as part of our Medical Injectables Program (MIP) administered by Magellan Rx Management℠.

The drug listed below, which was included on that announcement, has been removed from the MIP dating back to the previously announced March 1, 2018 effective date.

Generic Name

Brand Name

HCPCS

TISAGENLECLEUCEL

KYMRIAH

Q2040

Magellan Rx Management will NOT conduct medical necessity and appropriateness reviews (MNARs) for this injectable medication as part of the MIP. We apologize for any inconvenience.

Review the revised list of injectable medications that currently require Medical Necessity and Appropriateness Review (MNAR) as part of the MIP, or learn more about our Medical Injectables Program.

If you have questions, please contact your Network Specialist.

Magellan Rx Management℠ is a service mark of Magellan Health, Inc

Published on: May 7, 2018, 12:36 PM ET
Last updated on: May 7, 2018, 12:39 PM ET